Washington
Q3 2026Lobbying Q3 None last Q2 2025
YoY n/a vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
8 quarters Open in Washington ›
SGHT
Sight Sciences, Inc.$9.02 +0.03 (+0.33%)
Oct 26 4:00 PM ET · prev $8.99
Market cap
$500.7M
Small cap
Consensus
Buy
71% Buy or better · 14 analysts
Median target
$9.50
+5% · range $8.00–14.00
Next earnings
Nov 4
in 9 days · EPS est. −$0.12
1 year
+74.5%
from $5.17 · Oct 27
30 days
−2.7%
from $9.27
52-week range
$3.45–9.36
−4% from high · low Apr 10
Avg volume 20D
335.9K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$1.4M
1 buyer · 6 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 4, 2026
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- S Apr 1 to Apr 6 3 days of insider sells: $311.8K by 6 insiders, avg $3.58
- R Apr 23 Sight Sciences (SGHT) announced a final court judgment in its patent…
- S May 18 1 insider sell $65.2K at $5.12
- B Jun 10 1 insider buy $68.8K at $4.88
- S Jul 1 to Jul 6 3 days of insider sells: $448.4K by 6 insiders, avg $5.42
- X Aug 31 Short interest jumps 38.5% to 1.22M
- S Oct 1 to Oct 2 2 days of insider sells: $652.8K by 5 insiders, avg $8.95
- A Oct 15 HC Wainwright & Co. initiates
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $68.8K at an average $4.88. 6 insiders sold $1.5M. Price is 85% above their cost.
- InstitutionsMIXED
Q2 2026: 14 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
10 of 14 rate it Buy or better. Median target $9.50 (+5%).
- EstimatesRISING
Current-quarter EPS estimate −$0.160 → −$0.119 over 90 days. 2 up, 1 down in 30 days.
- TrendUPTREND
6% above its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| Pathstone Holdings, LLC | TRIM | $9.1M |
| Qube Research & Technologies Ltd | TRIM | $2.0M |
| PANAGORA ASSET MANAGEMENT INC | ADD | $1.4M |
| Squarepoint Ops LLC | TRIM | $1.2M |
| CITADEL ADVISORS LLC | ADD | $1.2M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $1.2M |
| GOLDMAN SACHS GROUP INC | ADD | $1.1M |
| UBS Group AG | TRIM | $683.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analysts 71% rate it Buy or better
12-month targets · 6 analysts
$9.02 $8.00 $9.50 $14.00
Price is inside the target range. Median implies +5%.Targets as of Oct 27, 2026.
Recent actions
| Date | Firm | Rating |
|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. INITIATE | Buy |
| Oct 5, 2026 | Citigroup MAINTAIN | Neutral |
| Aug 17, 2026 | Citigroup MAINTAIN | Neutral |
| Aug 6, 2026 | UBS MAINTAIN | Buy |
| Jul 8, 2026 | Citigroup MAINTAIN | Neutral |
| May 28, 2026 | Citigroup MAINTAIN | Neutral |
Insider ledger
Form 4$68.8K
bought · 1 insider
$1.5M
sold · 6 insiders
+84.9%
vs their $4.88 cost
| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 2, 2026 | Bauerlein Alison Chief Operating Officer | SELL | $223.6K |
| Oct 2, 2026 | Rodberg James Chief Financial Officer | SELL | $63.8K |
| Oct 2, 2026 | Taylor Brenton EVP, Operations & R&D | SELL | $26.5K |
| Oct 1, 2026 | Badawi Paul President and CEO | SELL | $268.3K |
| Oct 1, 2026 | Badawi David Chief Technology Officer | SELL | $70.6K |
| Aug 10, 2026 | Rashid Kashif Chief Legal Officer | AWARD | 181,818 sh |
| Jul 6, 2026 | HAYDEN JEREMY B. Chief Legal Officer | SELL | $70.1K |
| Jul 6, 2026 | Badawi David Chief Technology Officer | SELL | $40.9K |
Earnings setup
EstimatesNov 4
reports in 9 days
−$0.12
EPS estimate, this quarter
+25%
estimate change, 90 days
2↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
−$0.16090d
−$0.12760d
−$0.12730d
−$0.1277d
−$0.119Now
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.12 | -$0.15–-$0.08 | +6.2% | $23.5M |
| Next Q | -$0.13 | -$0.17–-$0.08 | +6.7% | $23.7M |
| Current FY | -$0.49 | -$0.64–-$0.28 | +0.4% | $90.3M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Sight Sciences, Inc. announced it will report its Q3 2026 results on November 4, 2026.
PRESS-RELEASE — Impact 1/10
Oct 21, 2026 Earnings
Oct 5, 2026 SEC Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sci
Sight Sciences CEO Paul Badawi and CTO David Badawi sold a combined $339K in open-market sales over a one-week window…
CLUSTER — Impact 3/10
Oct 2, 2026 Insider
Bauerlein Alison sold 25,260 shares
Chief Operating Officer @ $8.85 ($223.6K)
Oct 2, 2026 Insider
Rodberg James sold 7,208 shares
Chief Financial Officer @ $8.85 ($63.8K)
Oct 2, 2026 Insider
Aug 10, 2026 SEC Taylor Brenton sold 2,988 shares
EVP, Operations & R&D @ $8.85 ($26.5K)
Sight Sciences appointed Kashif Rashid as Chief Legal Officer and Corporate Secretary effective August 10, 2026…
8-K — Impact 2/10
Jun 30, 2026 Inst.
Pathstone Holdings, LLC — TRIM
1,678,980 shares ($9.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Oct 21, 2026
Earnings
Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology…
Oct 1, 2026
Company news
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company…
Sep 1, 2026
Press release
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology…
Aug 31, 2026
Short interest
Short Interest: SGHT up 38% to 1.2M shares
Settlement 2026-08-31 | Days to cover: 5.50 | ≈2.22% of shares outstanding (est.)
Aug 5, 2026
Earnings date
SGHT Q2 2026 Earnings Scheduled — 2026-08-05
SecBot reports
8 filings · 1 press release · 1 bullish · 2 bearish · 1 mixed · 4 neutral- NEUTRAL PRESS-RELEASEOct 21, 2026
Sight Sciences, Inc. announced it will report its Q3 2026 results on November 4, 2026.
- NEUTRAL CLUSTEROct 5, 2026
Sight Sciences CEO Paul Badawi and CTO David Badawi sold a combined $339K in open-market sales…
Sales are small relative to market cap and not clustered with a material business event. Monitor next 10-Q for any operational deterioration that might have prompted the CEO's sale.
- NEUTRAL 8-KAug 10, 2026
Sight Sciences appointed Kashif Rashid as Chief Legal Officer and Corporate Secretary effective…
No trading signal. This is a standard C-suite legal officer transition with orderly succession and no unexpected departures. Monitor next quarterly filing for any changes in legal strategy or…
- BEARISH CLUSTERJul 6, 2026
A multi-day insider selling cluster at Sight Sciences: five C-suite executives, including the CEO…
The breadth of C-suite selling (CEO, COO, CFO, CLO, CTO, EVP) in a short window is an unambiguous caution signal — especially notable given the stock trades ~$5.40, near multi-year lows. Monitor for…
All SGHT filing & press-release reports (9)
- PRESS-RELEASE reportOct 21, 2026
- CLUSTER reportOct 5, 2026
- 8-K reportAug 10, 2026
- CLUSTER reportJul 6, 2026
- 8-K reportApr 23, 2026
- PRESS-RELEASE reportApr 21, 2026
- CLUSTER reportApr 1, 2026
- 8-K reportMar 4, 2026
- PRESS-RELEASE reportMar 4, 2026